Besides, by comparing the expression of serum HCP5 in patients with primary gastric cancer, patients undergoing surgery, and patients with postoperative recurrence, we found that serum HCP5 rebounded in patients with tumor recurrence and it had the ability to monitor tumor dynamics. This evidence concerns the gene HCP5 and gastric cancer.